Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Blood

• Publication date

  1995-10-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD.V86.8.3035.BLOODJOURNAL8683035PMID 7579397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.

  1994cited by this paper
• A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.

  1994cited by this paper
• Alteration of fibrin network by activated protein C.

  1994cited by this paper
• Thrombin generation: An essential step in haemostasis and thrombosis

  1994cited by this paper
• A model for the tissue factor pathway to thrombin. I. An empirical study.

  1994cited by this paper
• Surface Independent Factor XI Activation by Thrombin in the Presence of High Molecular Weight Kininogen

  1994cited by this paper
• Factor XII-independent activation of factor XI in plasma: effects of sulfatides on tissue factor-induced coagulation.

  1993cited by this paper
• Activation of factor XI in plasma is dependent on factor XII.

  1993cited by this paper
• Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate.

  1992cited by this paper
• Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.

  1991cited by this paper
• Factor XI deficiency in Ashkenazi Jews in Israel.

  1991cited by this paper
• Factor XI activation in a revised model of blood coagulation

  1991cited by this paper
• Factor XI: A Review of Its Biochemistry and Deficiency

  1991cited by this paper
• The coagulation cascade: initiation, maintenance, and regulation.

  1991cited by this paper
• Effects of Poloxamer 188 on the Assembly, Structure and Dissolution of Fibrin Clots

  1991cited by this paper
• The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system.

  1990cited by this paper
• Comparative interactions of factor IX and factor IXa with human platelets.

  1989cited by this paper
• Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

  1989cited by this paper
• Role of the Contact System in Fibrinolysis

  1987cited by this paper
• Inhibition of human blood coagulation factor Xa by alpha 2-macroglobulin.

  1987cited by this paper
• INHIBITION OF HUMAN BLOOD COAGULATION FACTOR Xa BY α2-MACROGLO-BULIN

  1987cited by this paper
• Anticoagulantly active heparin-like molecules from vascular tissue.

  1984cited by this paper
• Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI.

  1983cited by this paper
• Properties of the factor Xa binding site on human platelets.

  1978cited by this paper

• Endothelial barrier disruption and contact system modulation during bacterial infection.

  2026cites this paper
• Thrombosis Caused by Factor XI Gly397Ser Mutation with Enhanced Procoagulant Activity

  2025cites this paper
• F9 missense variant hot spots associated with qualitative protein defects causing hemophilia B

  2025cites this paper
• New perspectives on the potential mechanisms, prevention and treatment of deep vein thrombosis complicated by lung cancer.

  2025cites this paper
• Factor XI inhibitors: is it time for a paradigm shift in anticoagulation?

  2025cites this paper
• Fibrin Monomer in Thrombosis and Haemostasis: A Clinical Biomarker and Beyond

  2025cites this paper
• Factor XII–driven coagulation traps bacterial infections

  2025cites this paper
• Factor XI Deficiency: Phenotypic Age related considerations and Clinical Approach Towards Bleeding Risk Assessment.

  2024cites this paper
• Clotting of the Extracorporeal Circuit in Hemodialysis: Beyond Contact-Activated Coagulation.

  2024cites this paper
• The current landscape of Factor XI inhibitors

  2024cites this paper
• Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation

  2023influential citation
• Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer

  2023cites this paper
• Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease

  2023cites this paper
• Reversal of factor XI targeting anticoagulants - an in vitro evaluation.

  2023cites this paper
• A new global fibrinolysis capacity assay for the sensitive detection of hyperfibrinolysis and hypofibrinogenemia in trauma patients.

  2023cites this paper
• Thrombin activation of the factor XI dimer is a multi-staged process for each subunit

  2023cites this paper
• Current antithrombotic therapies and prospects of natural compounds in the management of the thrombotic disorder

  2022cites this paper
• A FRET-based assay for the quantitation of the thrombin-factor XI interaction.

  2022cites this paper
• Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis

  2022cites this paper
• Factor XI, a potential target for anticoagulation therapy for venous thromboembolism

  2022cites this paper
• The clot lysis time‐based assay and the variability associated with interpretation of data

  2022cites this paper
• A demonstration of factor XI contributing to hemostasis in the absence of factor XII

  2022cites this paper
• VhH anti‐thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow

  2022cites this paper
• A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation

  2022cites this paper
• Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

  2022cites this paper
• Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease

  2022cites this paper
• Brazilian propolis (AF-08) inhibits collagen-induced platelet aggregation without affecting blood coagulation

  2021cites this paper
• Negatively charged phospholipids stimulate factor XI activation by thrombin

  2021cites this paper
• Hemostatic Testing in Critically Ill Infants and Children

  2021cites this paper
• Essential role of a carboxyl‐terminal α‐helix motif in the secretion of coagulation factor XI

  2021cites this paper
• Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

  2020cites this paper
• Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation

  2020cites this paper
• Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

  2020cites this paper
• Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19

  2020cites this paper
• The synthetic LPS binding peptide 19-2.5 interferes with clotting and prevents degradation of high molecular weight kininogen in plasma

  2020cites this paper
• Hemostatic control of adenotonsillectomy with recombinant Fc‐fused factor VIII in a boy with hemophilia A

  2020cites this paper
• Physiology of Haemostasis: Plasmin-Antiplasmin System

  2020cites this paper
• Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients

  2020cites this paper
• Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques

  2020cites this paper
• The evolution of factor XI and the kallikrein-kinin system.

  2020cites this paper
• Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo

  2020cites this paper
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.

  2020cites this paper
• Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation

  2020cites this paper
• In vitro evaluation of factor IX as novel treatment for factor XI deficiency

  2019cites this paper
• Tissue factor-related mechanisms of coagulation initiated on the virus envelope

  2019cites this paper
• Intrinsic Pathway of Coagulation and Thrombosis: Insights From Animal Models

  2019cites this paper
• Clot Structure and Implications for Bleeding and Thrombosis

  2019cites this paper
• Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis

  2019cites this paper
• Improving the understanding of plasma kallikrein contribution to arterial thrombus formation using two plant protease inhibitors

  2019cites this paper
• Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa

  2019cites this paper
• Fibrinolysis in trauma patients: wide variability demonstrated by the Lysis Timer

  2019cites this paper
• The reduced form of coagulation factor XI is associated with illness severity and coagulopathy in critically-ill septic patients

  2019cites this paper
• Category : Thrombosis and Hemostasis Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding Running title : Defective TAFI activation in hemophilia A

  2018cites this paper
• Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

  2018cites this paper
• Congenital Factor VII Deficiency

  2018cites this paper
• Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI

  2018cites this paper
• Thrombus Formation and Propagation in the Onset of Cardiovascular Events

  2018cites this paper
• Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

  2018cites this paper
• Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.

  2017cites this paper
• Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation

  2017cites this paper
• Factor XI deficiency enhances the pulmonary allergic response to house dust mite in mice independent of factor XII.

  2017cites this paper
• Macrocyclic factor XIa inhibitors.

  2017cites this paper
• Platelets and Fibrinolysis

  2017cites this paper
• Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis

  2016cites this paper
• Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin‐independent impairment of the thrombin‐activatable fibrinolysis inhibitor pathway

  2016cites this paper
• Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis

  2016cites this paper
• Is resistance futile? The role of activated thrombin‐activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency

  2016cites this paper
• Effect of thrombin inhibitors on positive feedback in the coagulation cascade

  2016cites this paper
• Contact-Activation Pathways as Targets for New Anticoagulants

  2016cites this paper
• Factor concentrates for rare congenital coagulation disorders: where are we now?

  2016cites this paper
• Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics

  2016cites this paper
• New Tools to Study Contact Activation

  2016cites this paper
• Is resistance futile? The role of TAFIa resistance in bleeding in FXI deficiency

  2016cites this paper
• Plasmin-Antiplasmin System

  2016cites this paper
• Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen

  2016cites this paper
• Multifunctional Roles o f Thrombin *

  2015cites this paper
• Adverse effects of glucocorticoids: coagulopathy.

  2015cites this paper
• Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency.

  2015cites this paper
• Hemostasis and thrombosis beyond biochemistry: roles of geometry, flow and diffusion.

  2015cites this paper
• Thrombin generation measured in platelet rich plasma with contact activation inhibition identifies bleeding phenotype in FXI deficiency. Abstract Individuals with FXI deficiency have a variable bleeding tendency which does not correlate with FXI:C

  2015cites this paper
• THROMBOSIS AND HEMOSTASIS Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI de fi ciency

  2015cites this paper
• Quality of factor XI activity testing in North American Specialized Coagulation Laboratories

  2015cites this paper
• Normal Coagulation and Hemostasis

  2014cites this paper
• Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency

  2014cites this paper
• Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay.

  2014cites this paper
• Synthetic, Sulfated, Lignin-Based Anticoagulants

  2014cites this paper
• Investigating the role of Von Willebrand Factor in Fibrin Formation and Fibrinolysis

  2014cites this paper
• The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood

  2014cites this paper
• Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

  2014cites this paper
• An update on recent patents on thrombin inhibitors (2010 – 2013)

  2014cites this paper
• N248 to activated human platelets - Defective binding of factor XI

  2013cites this paper
• Models for thrombin generation and risk of disease

  2013cites this paper
• Computer-aided design of novel antithrombotic agents

  2013cites this paper
• Factor IX-Padua enhances the fibrinolytic resistance of plasma clots

  2013cites this paper
• Fibrin Facilitates Both Innate and T Cell–Mediated Defense against Yersinia pestis

  2013cites this paper
• Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients

  2013cites this paper
• patients with inherited factor XI deficiency Prevalence, causes, and characterization of factor XI inhibitors in

  2013cites this paper
• A fibrinogen concentrate Haemocomplettan® (Riastap®) or a Factor XIII concentrate Fibrogammin® combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin‐ or FXa‐inhibitor

  2013cites this paper
• Marine sulfated glycans with serpin-unrelated anticoagulant properties.

  2013cites this paper
• Experimental Human Endotoxemia Activation of Clotting Factor XI Without Detectable Contact Activation in

  2013cites this paper